The medical device company agreed to lower the exercise price on outstanding November 2025 warrants and issue two new series of private placement warrants tied to 857,462 shares.
Autonomix Medical said it entered into a warrant inducement agreement with an investor for the immediate exercise of outstanding warrants issued in November 2025, a transaction expected to generate about $2.6 million in gross proceeds before fees and expenses. The investor agreed to exercise warrants for 428,731 common shares at an amended exercise price of $6.00 per share, while Autonomix agreed to issue unregistered Series D-1 and Series D-2 warrants covering 428,731 shares each. The new warrants carry a $5.75 exercise price, are exercisable immediately upon issuance, and expire five and a half years from issuance. Closing is expected on or about July 15, 2026, subject to customary conditions. Maxim Group LLC acted as warrant inducement agent and financial advisor. Autonomix said it will file a registration statement with the SEC covering the resale of shares issuable on exercise of the new warrants. The company develops nerve-targeted medical technology, including a catheter-based microchip sensing array aimed initially at pain treatment in pancreatic cancer.